A novel plant-produced Pfs25 fusion subunit vaccine induces long-lasting transmission blocking antibody responses

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 1, 2015, Pages 124-132

  Jones, R Mark ^a   Chichester, Jessica A ^a   Manceva, Slobodanka ^a   Gibbs, Sandra K ^a   Musiychuk, Konstantin ^a   Shamloul, Moneim ^a   Norikane, Joey ^a   Streatfield, Stephen J ^a   Van De Vegte Bolmer, Marga ^b   Roeffen, Will ^b   Sauerwein, Robert W ^b   Yusibov, Vidadi ^a  

^a USA Center for Molecular Biotechnology   (United States)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Fusion protein; Lichenase; Malaria; Pfs25; Plant produced antigen; Plasmodium falciparum; Subunit vaccine; Transmission blocking vaccine

Indexed keywords

CARRIER PROTEIN; GLYCOSIDASE; HYBRID PROTEIN; LICHENINASE; MALARIA VACCINE; PFS25 PROTEIN, PLASMODIUM FALCIPARUM; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY; RECOMBINANT VACCINE; SUBUNIT VACCINE;

ANIMAL; BAGG ALBINO MOUSE; BLOOD; DISEASE TRANSMISSION; FEMALE; GENE EXPRESSION; GENE VECTOR; GENETICS; IMMUNOLOGY; MALARIA; METABOLISM; PLASMODIUM FALCIPARUM; POTYVIRUS; PREVENTION AND CONTROL; RABBIT; TIME FACTOR; TOBACCO; TRANSGENIC PLANT;

ANIMALS; ANTIBODIES, PROTOZOAN; CARRIER PROTEINS; DISEASE TRANSMISSION, INFECTIOUS; FEMALE; GENE EXPRESSION; GENETIC VECTORS; GLYCOSIDE HYDROLASES; MALARIA; MALARIA VACCINES; MICE, INBRED BALB C; PLANTS, GENETICALLY MODIFIED; PLASMODIUM FALCIPARUM; POTYVIRUS; PROTOZOAN PROTEINS; RABBITS; RECOMBINANT FUSION PROTEINS; TIME FACTORS; TOBACCO; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 84949115252     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.34366     Document Type: Conference Paper

References (38)

1. World Health Organization. Malaria. Fact sheet No 94. http://www.who.int/mediacentre/factsheets/fs094/en/ (accessed 19 May 2014).
2. Roll Back Malaria. Key malaria facts. http://www.rollbackmalaria.org/keyfacts.html (accessed 19 May 2014).
3. World Health Organization. Guidelines for the treatment of malaria. 2d Ed., 2010. http://whqlibdoc.who.int/publications/2010/9789241547925-eng.pdf.
4. Hill AV. Vaccines against malaria. Philos Trans R Soc Lond B Biol Sci 2011; 366:2806-14; PMID:21893544; http://dx.doi.org/10.1098/rstb.2011.0091
5. Thera MA, Plowe CV. Vaccines for malaria: how close are we? Annu Rev Med 2012; 63:345-57; PMID:22077719; http://dx.doi.org/10.1146/annurev-med-022411-192402
6. Aly ASI, Vaughan AM, Kappe SHI. Malaria parasite development in the mosquito and infection of the mammalian host. Annu Rev Microbiol 2009; 63:195-221; PMID:19575563; http://dx.doi.org/10.1146/annurev.micro.091208.073403
7. Vermeulen AN, Ponnudurai T, Beckers PJ, Verhave JP, Smits MA, Meuwissen JH. Sequential expression of antigens on sexual stages of Plasmodium falciparum accessible to transmission-blocking antibodies in the mosquito. J Exp Med 1985; 162:1460-76; PMID:2865324; http://dx.doi.org/10.1084/jem.162.5.1460
8. Kaslow DC, Quakyi IA, Syin C, Raum MG, Keister DB, Coligan JE, McCutchan TF, Miller LH. A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature 1988; 333:74-6; PMID:3283563; http://dx.doi.org/10.1038/333074a0
9. Samuelson J, Banerjee S, Magnelli P, Cui J, Kelleher DJ, Gilmore R, Robbins PW. The diversity of dolichol-linked precursors to Asn-linked glycans likely results from secondary loss of sets of glycosyltransferases. Proc Natl Acad Sci U S A 2005; 102:1548-53; PMID:15665075; http://dx.doi.org/10.1073/pnas.0409460102
10. Barr PJ, Green KM, Gibson HL, Bathurst IC, Quakyi IA, Kaslow DC. Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals. J Exp Med 1991; 174:1203-8; PMID:1940798; http://dx.doi.org/10.1084/jem.174.5.1203
11. Kaslow DC, Bathurst IC, Lensen T, Ponnudurai T, Barr PJ, Keister DB. Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum. Infect Immun 1994; 62:5576-80; PMID:7960139
12. Zou L, Miles AP, Wang J, Stowers AW. Expression of malaria transmission-blocking vaccine antigen Pfs25 in Pichia pastoris for use in human clinical trials. Vaccine 2003; 21:1650-7; PMID:12639486; http://dx.doi.org/10.1016/S0264-410X(02)00701-6
13. Wu Y, Przysiecki C, Flanagan E, Bello-Irizarry SN, Ionescu R, Muratova O, Dobrescu G, Lambert L, Keister D, Rippeon Y, et al. Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex. Proc Natl Acad Sci U S A 2006; 103:18243-8; PMID:17110440; http://dx.doi.org/10.1073/pnas.0608545103
14. Qian F, Wu Y, Muratova O, Zhou H, Dobrescu G, Duggan P, Lynn L, Song G, Zhang Y, Reiter K, et al. Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates. Vaccine 2007; 25:3923-33; PMID:17428587; http://dx.doi.org/10.1016/j.vaccine.2007.02.073
15. Kubler-Kielb J, Majadly F, Wu Y, Narum DL, Guo C, Miller LH, Shiloach J, Robbins JB, Schneerson R. Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25. Proc Natl Acad Sci U S A 2007; 104:293-8; PMID:17190797; http://dx.doi.org/10.1073/pnas.0609885104
16. Qian F, Rausch KM, Muratova O, Zhou H, Song G, Diouf A, Lambert L, Narum DL, Wu Y, Saul A, et al. Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders. Vaccine 2008; 26:2521-7; PMID:18423804; http://dx.doi.org/10.1016/j.vaccine.2008.03.005
17. ClinicalTrials.gov. Initial Study of Malaria Vaccine Pfs25-EPA/Alhydrogel. http://www.clinicaltrials.gov/ct2/show/NCT01434381?term=Pfs25-EPA&rank=2 (accessed 30 May 2014).
18. Rybicki EP. Plant-made vaccines for humans and animals. Plant Biotechnol J 2010; 8:620-37; PMID:20233333; http://dx.doi.org/10.1111/j.1467-7652.2010.00507.x
19. Yusibov V, Streatfield SJ, Kushnir N. Clinical development of plant-produced recombinant pharmaceuticals: vaccines, antibodies and beyond. Hum Vaccin 2011; 7:313-21; PMID:21346417; http://dx.doi.org/10.4161/hv.7.3.14207
20. Musiychuk K, Stephenson N, Bi H, Farrance CE, Orozovic G, Brodelius M, Brodelius P, Horsey A, Ugulava N, Shamloul AM, et al. A launch vector for the production of vaccine antigens in plants. Influenza Other Respir Viruses 2007; 1:19-25; PMID:19453476; http://dx.doi.org/10.1111/j.1750-2659.2006.00005.x
21. Chichester JA, Musiychuk K, de la Rosa P, Horsey A, Stevenson N, Ugulava N, Rabindran S, Palmer GA, Mett V, Yusibov V. Immunogenicity of a sub-unit vaccine against Bacillus anthracis. Vaccine 2007; 25:3111-4; PMID:17280756; http://dx.doi.org/10.1016/j.vaccine.2007.01.068
22. Chichester JA, Musiychuk K, Farrance CE, Mett V, Lyons J, Mett V, Yusibov V. A single component two-valent LcrV-F1 vaccine protects non-human primates against pneumonic plague. Vaccine 2009; 27:3471-4; PMID:19200825; http://dx.doi.org/10.1016/j.vaccine.2009.01.050
23. Mett V, Musiychuk K, Bi H, Farrance CE, Horsey A, Ugulava N, Shoji Y, de la Rosa P, Palmer GA, Rabindran S, et al. A plant-produced influenza subunit vaccine protects ferrets against virus challenge. Influenza Other Respir Viruses 2008; 2:33-40; PMID:19453491; http://dx.doi.org/10.1111/j.1750-2659.2008.00037.x
24. Shoji Y, Chichester JA, Bi H, Musiychuk K, de la Rosa P, Goldschmidt L, Horsey A, Ugulava N, Palmer GA, Mett V, et al. Plant-expressed HA as a seasonal influenza vaccine candidate. Vaccine 2008; 26:2930-4; PMID:18440103; http://dx.doi.org/10.1016/j.vaccine.2008.03.045
25. Shoji Y, Bi H, Musiychuk K, Rhee A, Horsey A, Roy G, Green B, Shamloul M, Farrance CE, Taggart B, et al. Plant-derived hemagglutinin protects ferrets against challenge infection with the A/Indonesia/05/05 strain of avian influenza. Vaccine 2009; 27:1087-92; PMID:19100806; http://dx.doi.org/10.1016/j.vaccine.2008.11.108
26. Shoji Y, Farrance CE, Bi H, Shamloul M, Green B, Manceva S, Rhee A, Ugulava N, Roy G, Musiychuk K, et al. Immunogenicity of hemagglutinin from A/Bar-headed Goose/Qinghai/1A/05 and A/Anhui/1/05 strains of H5N1 influenza viruses produced in Nicotiana benthamiana plants. Vaccine 2009; 27:3467-70; PMID:19200814; http://dx.doi.org/10.1016/j.vaccine.2009.01.051
27. Shoji Y, Chichester JA, Jones M, Manceva SD, Damon E, Mett V, Musiychuk K, Bi H, Farrance C, Shamloul M, et al. Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza. Hum Vaccin 2011; 7(Suppl):41-50; PMID:21266846; http://dx.doi.org/10.4161/hv.7.0.14561
28. Farrance CE, Chichester JA, Musiychuk K, Shamloul M, Rhee A, Manceva SD, Jones RM, Mamedov T, Sharma S, Mett V, et al. Antibodies to plant-produced Plasmodium falciparum sexual stage protein Pfs25 exhibit transmission blocking activity. Hum Vaccin 2011; 7(Suppl):191-8; PMID:21266847; http://dx.doi.org/10.4161/hv.7.0.14588
29. Matsuoka M, Yamamoto N, Kano-Murakami Y, Tanaka Y, Ozeki Y, Hirano H, Kagawa H, Oshima M, Ohashi Y. Classification and structural comparison of full-length cDNAs for pathogenesis-related proteins. Plant Physiol 1987; 85:942-6; PMID:16665835; http://dx.doi.org/10.1104/pp.85.4.942
30. malERA Consultative Group on Vaccines. A research agenda for malaria eradication: vaccines. PLoS Med 2011; 8:e1000398; PMID:21311586; http://dx.doi.org/10.1371/journal.pmed.1000398
31. Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, Mahanty S, Fay MP, Narum D, Rausch K, Miles AP, et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One 2008; 3:e2636; PMID:18612426; http://dx.doi.org/10.1371/journal.pone.0002636
32. Miura K, Keister DB, Muratova OV, Sattabongkot J, Long CA, Saul A. Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer. Malar J 2007; 6:107; PMID:17686163; http://dx.doi.org/10.1186/1475-2875-6-107
33. Shimp RL Jr., Rowe C, Reiter K, Chen B, Nguyen V, Aebig J, Rausch KM, Kumar K, Wu Y, Jin AJ, et al. Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle. Vaccine 2013; 31:2954-62; PMID:23623858; http://dx.doi.org/10.1016/j.vaccine.2013.04.034
34. st annual Meeting. Atlanta, GA, USA. Nov 11-15, 2012. Abstract #1455.
35. Edelhoch H. Spectroscopic determination of tryptophan and tyrosine in proteins. Biochemistry 1967; 6:1948-54; PMID:6049437; http://dx.doi.org/10.1021/bi00859a010
36. Pace CN, Vajdos F, Fee L, Grimsley G, Gray T. How to measure and predict the molar absorption coefficient of a protein. Protein Sci 1995; 4:2411-23; PMID:8563639; http://dx.doi.org/10.1002/pro.5560041120
37. Roeffen W, Geeraedts F, Eling W, Beckers P, Wizel B, Kumar N, Lensen T, Sauerwein R. Transmission blockade of Plasmodium falciparum malaria by anti-Pfs230-specific antibodies is isotype dependent. Infect Immun 1995; 63:467-71; PMID:7822011
38. Outchkourov N, Vermunt A, Jansen J, Kaan A, Roeffen W, Teelen K, Lasonder E, Braks A, van de Vegte-Bolmer M, Qiu LY, et al. Epitope analysis of the malaria surface antigen pfs48/45 identifies a subdomain that elicits transmission blocking antibodies. J Biol Chem 2007; 282:17148-56; PMID:17426022; http://dx.doi.org/10.1074/jbc.M700948200